New hope for advanced cancer: first human trial of ALK201 begins

NCT ID NCT06656390

Recruiting now Disease control Sponsor: Shanghai Allink Biotherapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug, ALK201, for the first time in people with advanced solid tumors that have not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 202 adults aged 18 to 75 will take part. The study is currently recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER ADVANCED SOLID TUMORS

Contacts and locations

Locations

Affiliated Hospital of Chengde Medical University
RECRUITING

Chengde, Hebei, China
Anhui Provincial Cancer Hospital
RECRUITING

Hefei, Anhui, China
Cancer Care Wollongong
RECRUITING

Wollongong, New South Wales, 2500, Australia
Cancer Hospital Of Shantou University Medical College
RECRUITING

Shantou, Guangdong, China
ChongQing University Cancer Hospital
RECRUITING

Chongqing, China
Denver Drug Development Unit
RECRUITING

Denver, Colorado, 80218, United States
First Affiliated Hospital of Gannan Medical University
RECRUITING

Ganzhou, Jiangxi, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, China
Guangdong Province People's Hospital
RECRUITING

Guangzhou, Guangdong, China
Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, China
Harbin Medical University Canser Hospital
RECRUITING

Harbin, Heilongjiang, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Jiangsu Province Hospital
RECRUITING

Nanjing, Jiangsu, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, China
Macquarie University Hospital
RECRUITING

Macquarie, Australia
Mater Cancer Care Center
RECRUITING

South Brisbane, Queensland, Australia
Sarah Cannon Research Institute Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, China
Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200000, China
Sir Run Run Shaw Hospital Zhejiang University School of Medical
RECRUITING

Hangzhou, Zhejiang, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China
Sunshine Coast University Private Hospital
RECRUITING

Birtinya, Queensland, Australia
The Central Hospital of Yongzhou
RECRUITING

Yongzhou, Hunan, China
The First Affiliated Hospital Of Xiamen University
RECRUITING

Xiamen, Fujian, China
The First Affiliated Hospital Zhejiang University School Of Medicine
RECRUITING

Hangzhou, Zhejiang, China
The First Affiliated Hospital of Henan University of Science & Technology
RECRUITING

Luoyang, Henan, China
The First People's Hospital of Changzhou
RECRUITING

Changzhou, Jiangsu, China
The Second Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, China
Tongji Hospital, Tongji Medical College of Hust
RECRUITING

Wuhan, Hubei, China
UCF Lake Nona Cancer Center
RECRUITING

Orlando, Florida, 32827, United States
Union Hospital, Tongji Medical College,Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China
University Medical Center New Orleans
RECRUITING

New Orleans, Louisiana, 70112, United States
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, China
Xuzhou Central Hospital ( Southeast University Affiliated Hopstal )
RECRUITING

Xuzhou, Jiangsu, China
Yunnan Cancer Hospital
RECRUITING

Kunming, Yunnan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.